NUMD
Nu-Med Plus, Inc.0.0184
-0.0060-24.6%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.54MP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
10-Q
10-Q
Q2 FY2025 results
Nu-Med Plus posted a narrower net loss of $11,665 for Q2 ended June 30, 2025, down 32.5% y/y from $17,287, while YTD losses shrank to $31,598 from $39,112, or 19.2% y/y, thanks to trimmed operating expenses like dues and subscriptions. No revenue yet, as the early-stage medtech firm hones nitric oxide delivery tech amid funding hunts. Cash dipped to $863 from $2,373 at year-start, with operating cash burn at $1,510 YTD; a $100,000 related-party note payable looms due December 31, 2025. Post-quarter, officers chipped in $14,000 for ops. Stockholders' deficit widened to $246,694. Funding remains the crux.
10-Q
Q1 FY2025 results
Nu-Med Plus posted a narrower net loss of $19,933 for Q1 FY2025 ended March 31, 2025, down from $21,826 a year earlier, thanks to operating expenses dropping 9.2% y/y to $18,700 (derived) on lower professional and consulting fees. Interest expense ticked down slightly to $1,233, while revenue stayed at zero amid suspended product development. Cash held steady at $2,373, with zero net cash used in operations, but liabilities climbed to $240,202, deepening the working capital deficit to $235,029. No free cash flow or non-GAAP metrics disclosed in the 10-Q. Funding needs loom large at $1.2M over the next year. Development stalled without capital. Cybersecurity threats pose ongoing risks to operations.
10-K
FY2024 results
NU-MED Plus reported no revenue for FY2024 ended December 31, 2024, with operating expenses dropping to $63,331 from $120,526 in 2023, yielding a net loss of $68,345 versus $125,526 the prior year; the narrower loss stemmed from slashed stock-based compensation, rent, and professional fees, but quarterly breakdowns remain undisclosed in the 10-K. Development of nitric oxide delivery prototypes halted amid funding shortages, leaving cash at a mere $2,373 against $224,469 in liabilities, sufficient for just two more months without fresh capital. No dividends, buybacks, or capex materialized. The company eyes mergers and patent filings, yet auditors flag substantial going-concern doubts. We lack funding to advance. Regulatory delays loom large, potentially stalling quarterly progress indefinitely.
10-Q
Q3 FY2024 results
Nu-Med Plus reported no revenue for Q3 FY2024 ended September 30, 2024, with operating expenses up 15% y/y to $17,417 from $15,146, driven by higher professional fees and filing costs, while rent expense dropped to zero. This yielded an operating loss of $17,417, widening 15% y/y, and a net loss of $18,677 after $1,260 interest, compared to $16,406 last year. For the nine months, operating expenses fell 17% y/y to $54,037, trimming the net loss to $57,790 from $68,930, thanks to lower legal and rent outlays. Cash dwindled to $4,041 from $6,806 year-end, with net operating cash use at $2,765 versus $62,107 prior year; a $100,000 note payable persists alongside $111,329 in payables. The planned merger with YourSpace America collapsed in October 2024, forcing a leadership shuffle. No free cash flow disclosed in the 10-Q. Funding remains the core risk.
EMED
Electromedical Technologies, In
0.00+0.00
HSDT
Solana Company
3.10+0.06
MDNC
MEDINOTEC INC
5.00+0.00
MODD
Modular Medical, Inc.
0.34-0.03
NAOV
NanoVibronix, Inc.
4.02-0.29
NUWE
Nuwellis, Inc.
2.21+0.03
NVNO
enVVeno Medical Corporation
0.32+0.01
NXL
Nexalin Technology, Inc.
0.81-0.01
PMI
Picard Medical, Inc.
2.30-0.13
SNWV
SANUWAVE Health, Inc.
31.46-0.18